Rezolute, Inc. 8-K

What Happened Rezolute, Inc. (RZLT) filed a Current Report on Form 8-K on January 7, 2026 announcing additional clinical information related to its sunRIZE trial. The company furnished a press release, a cumulative data table covering the initial nine tumor HI participants in the expanded access program (EAP), and an updated corporate presentation. The EAP table details patient characteristics, ersodetug dosing, and the observed outcomes for those nine participants.

Key Details

• Date filed: January 7, 2026.
• EAP dataset covers the initial 9 tumor HI participants, with patient characteristics, ersodetug dosing, and observed outcomes reported.
• Materials furnished: press release, EAP data table, and updated corporate deck (Exhibits 99.1–99.3).
• Rezolute states these furnished materials are not “filed” for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings unless explicitly stated.

Why It Matters This 8-K provides investors with early, concrete clinical information about ersodetug and progress in the sunRIZE program, helping assess clinical momentum and near-term development milestones. The dataset is small (nine EAP participants), so while useful for tracking progress and transparency, it is preliminary and not a substitute for larger trial results or formal efficacy/safety conclusions. The company did not report financial results or corporate leadership changes in this filing.